Analysis of clinical features and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis

Analysis of clinical features and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis - Analysis of clinical features and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036873

Enrollment

400

Registered

2019-06-01

Start date

2019-05-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anti-neutrophil cytoplasmic antibody associated vasculitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with vasculitis, whose ANCA is positive, attending Clinical Immunology and Rheumatology, Jichi Medical University Hospital.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
To study outcomes of relapses, occurrences of adverse events, discontinuing of immunosuppressants, and survival rate, for five years.	—

Countries

Japan

Contacts

Public ContactTakamasa Murosaki

Jichi Medical University Hospital Clinical Immunology and Rheumatology

r0752tm@jichi.ac.jp0285587358

Outcome results